Very recently, Jinushi et al. [42] evaluate lactadherin as a general target for anti-tumor therapy showing that antibodies directed to lactadherin in combination with conventional anti-tumor treatments enhances drug-induced apoptosis, stimulates T cell immunity, increases dendritic cell cross-presentation of tumor antigens and modulates dendritic cell cytokine production. This evidence concerns the gene MFGE8 and neoplasm.